{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:47:03Z","timestamp":1788580023390,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T00:00:00Z","timestamp":1346025600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with rheumatoid arthritis (RA) are known to be at increased risk of infection, particularly if they are taking drugs with immunomodulatory effects. There is a need for more information on the risk of influenza in patients with RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective cohort study was carried out using data gathered from a large US commercial health insurance database (Thomson Reuters Medstat MarketScan) from 1 January 2000 to 31 December 2007. Patients were \u226518 years of age, with at least two RA claims diagnoses. The database was scanned for incidence of seasonal influenza and its complications on or up to 30 days after an influenza diagnosis in RA patients and matched controls. Other factors accounted for included medical conditions, use of disease-modifying anti-rheumatic drugs (DMARDs), use of biological agents, influenza vaccination and high- or low-dose corticosteroids. Incidence rate ratios (IRRs) were calculated for influenza and its complications in patients with RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>46,030 patients with RA and a matching number of controls had a median age of 57 years. The incidence of influenza was higher in RA patients than in controls (409.33 vs 306.12 cases per 100,000 patient-years), and there was a 2.75-fold increase in incidence of complications in RA. Presence or absence of DMARDs or biologics had no significant effect. The adjusted IRR of influenza was statistically significant in patients aged 60\u201369 years, and especially among men. A significantly increased rate of influenza complications was observed in women and in both genders combined (but not in men only) when all age groups were combined. In general, the risk of influenza complications was similar in RA patients not receiving DMARDs or biologics to that in all RA patients. Pneumonia rates were significantly higher in women with RA. Rates of stroke\/myocardial infarction (MI) were higher in men, although statistical significance was borderline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>RA is associated with increased incidence of seasonal influenza and its complications. Gender- and age-specific subgroup data indicate that women generally have a greater rate of complications than men, but that men primarily have an increased rate of stroke and MI complications. Concomitant DMARD or biological use appears not to significantly affect the rate of influenza or its complications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2474-13-158","type":"journal-article","created":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T10:14:25Z","timestamp":1346062465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study"],"prefix":"10.1186","volume":"13","author":[{"given":"William A","family":"Blumentals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Arreglado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Napalkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Toovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"1484_CR1","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46: 2287-2293. 10.1002\/art.10524.","journal-title":"Arthritis Rheum"},{"key":"1484_CR2","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1086\/587063","volume":"46","author":"T Gl\u00fcck","year":"2008","unstructured":"Gl\u00fcck T, M\u00fcller-Ladner U: Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008, 46: 1459-1465. 10.1086\/587063.","journal-title":"Clin Infect Dis"},{"key":"1484_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/art.1780140119","volume":"14","author":"J Baum","year":"1971","unstructured":"Baum J: Infection in rheumatoid arthritis. Arthritis Rheum. 1971, 14: 135-137. 10.1002\/art.1780140119.","journal-title":"Arthritis Rheum"},{"key":"1484_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/anr.1780320422","volume":"32","author":"DL Goldenberg","year":"1989","unstructured":"Goldenberg DL: Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders. Arthritis Rheum. 1989, 32: 496-502. 10.1002\/anr.1780320422.","journal-title":"Arthritis Rheum"},{"key":"1484_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7861\/clinmedicine.10-4-326","volume":"10","author":"MM Housden","year":"2010","unstructured":"Housden MM, Bell G, Heycock CR, Hamilton J, Saravanan V, Kelly CA: How to reduce morbidity and mortality from chest infections in rheumatoid arthritis. Clin Med. 2010, 10: 326-329.","journal-title":"Clin Med"},{"key":"1484_CR6","first-page":"2857","volume":"43","author":"S Gershon","year":"2000","unstructured":"Gershon S, Wise RP, Niu M, Siegel J: Postlicensure reports of infection during use of etanercept and infliximab [abstract]. Arthritis Rheum. 2000, 43: 2857-","journal-title":"Arthritis Rheum"},{"key":"1484_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0025-6196(11)62418-X","volume":"76","author":"M Baghai","year":"2001","unstructured":"Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001, 76: 653-656.","journal-title":"Mayo Clin Proc"},{"key":"1484_CR8","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/art.10583","volume":"46","author":"JH Lee","year":"2002","unstructured":"Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002, 46: 2565-2570. 10.1002\/art.10583.","journal-title":"Arthritis Rheum"},{"key":"1484_CR9","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.3399\/bjgp09X472629","volume":"59","author":"Y Vinogradova","year":"2009","unstructured":"Vinogradova Y, Hippisley-Cox J, Coupland C: Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract. 2009, 59: e329-e338.","journal-title":"Br J Gen Pract"},{"key":"1484_CR10","volume-title":"PL CMO (2005)1: the Pneumococcal Immunisation Programme for Older People and Risk Groups","author":"Department of Health","year":"2009","unstructured":"Department of Health: PL CMO (2005)1: the Pneumococcal Immunisation Programme for Older People and Risk Groups. 2009, London: Department of Health,http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Lettersandcirculars\/Professionalletters\/Chiefmedicalofficerletters\/DH_4107903,"},{"key":"1484_CR11","volume-title":"Influenza (flu). Risk factors. 21","author":"Mayo Clinic","year":"2010","unstructured":"Mayo Clinic: Influenza (flu). Risk factors. 21. 2010,http:\/\/www.mayoclinic.com\/health\/influenza\/DS00081\/DSECTION=risk-factors, August ,"},{"key":"1484_CR12","volume-title":"Pharmaceuticals: Data, Databases and Online Tools: Marketscan Research Databases","author":"Thomson Reuters","year":"2011","unstructured":"Thomson Reuters: Pharmaceuticals: Data, Databases and Online Tools: Marketscan Research Databases. 2011, New York, NY, USA: Thomson Reuters,http:\/\/thomsonreuters.com\/products_services\/healthcare\/healthcare_products\/pharmaceuticals\/mktscan_res_db\/,"},{"key":"1484_CR13","volume-title":"Classification of diseases, functioning, and disability. International Classification of Diseases, Ninth Revision (ICD-9)","author":"Centers for Disease Control and Prevention","year":"2009","unstructured":"Centers for Disease Control and Prevention: Classification of diseases, functioning, and disability. International Classification of Diseases, Ninth Revision (ICD-9). 2009, Atlanta, GA, USA: CDC,http:\/\/www.cdc.gov\/nchs\/icd\/icd9.htm,"},{"key":"1484_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.autrev.2008.07.010","volume":"8","author":"M Cutolo","year":"2008","unstructured":"Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, Montagna P, Sulli A: Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008, 8: 153-155. 10.1016\/j.autrev.2008.07.010.","journal-title":"Autoimmun Rev"},{"key":"1484_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jbspin.2010.02.009","volume":"77","author":"A Ruyssen-Witrand","year":"2010","unstructured":"Ruyssen-Witrand A, Fautrel B, Saraux A, Le-Lo\u00ebt X, Pham T: Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2010, 77: 246-251. 10.1016\/j.jbspin.2010.02.009.","journal-title":"Joint Bone Spine"},{"key":"1484_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00002281-200309000-00002","volume":"15","author":"I Kang","year":"2003","unstructured":"Kang I, Park SH: Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003, 15: 528-534. 10.1097\/00002281-200309000-00002.","journal-title":"Curr Opin Rheumatol"},{"key":"1484_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/1471-2334-10-256","volume":"10","author":"X Xi","year":"2010","unstructured":"Xi X, Xu Y, Jiang L, Li A, Duan J, Du B: Chinese Critical Care Clinical Trial Group: Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing China: risk factors for hospital mortality. BMC Infect Dis. 2010, 10: 256-","journal-title":"BMC Infect Dis"},{"key":"1484_CR18","first-page":"124","volume":"3","author":"WS Mitchell","year":"1976","unstructured":"Mitchell WS, Brooks PM, Stevenson RD, Buchanan WW: Septic arthritis in patients with rheumatoid disease: a still underdiagnosed complication. J Rheumatol. 1976, 3: 124-133.","journal-title":"J Rheumatol"},{"key":"1484_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jama.1966.03100200057018","volume":"196","author":"DL Rimoin","year":"1966","unstructured":"Rimoin DL, Wennberg JE: Acute septic arthritis complicating chronic rheumatoid arthritis. JAMA. 1966, 196: 617-621. 10.1001\/jama.1966.03100200057018.","journal-title":"JAMA"},{"key":"1484_CR20","doi-asserted-by":"publisher","first-page":"9203","DOI":"10.1073\/pnas.97.16.9203","volume":"97","author":"K Koetz","year":"2000","unstructured":"Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM: T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 2000, 97: 9203-9208. 10.1073\/pnas.97.16.9203.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 48","key":"1484_CR21","first-page":"S67","volume":"26","author":"F Atzeni","year":"2008","unstructured":"Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P: Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol. 2008, 26 (Suppl 48): S67-S73.","journal-title":"Clin Exp Rheumatol"},{"key":"1484_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE: The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010, 39: 327-346. 10.1016\/j.semarthrit.2008.10.002.","journal-title":"Semin Arthritis Rheum"},{"key":"1484_CR23","volume-title":"US Food and Drug Administration: Tumor Necrosis Factor-alpha (TNF\u03b1) Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria including Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certoli","author":"FDA","year":"2011","unstructured":"FDA: US Food and Drug Administration: Tumor Necrosis Factor-alpha (TNF\u03b1) Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria including Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golimumab). FDA. 2011,http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm270977.htm,"},{"issue":"Suppl 3","key":"1484_CR24","first-page":"117","volume":"70","author":"A Ribeiro","year":"2011","unstructured":"Ribeiro A, Guedes L, Moraes J, Saad C, Aikawa N, Calish A, Fran\u00e7a I, Gon\u00e7alves C, Sampaio-Barros P, Carvalho J, Borba E, Timenetsky M, Precioso A, Duarte A, Bonfa E, Laurindo I: Implications of reduced seroprotection (SP) after pandemic H1N1 (2009) influenza adjuvant-free vaccination in patients with rheumatoid arthritis on active systemic treatment (classical and biologic DMARDS). Ann Rheum Dis. 2011, 70 (Suppl 3): 117-","journal-title":"Ann Rheum Dis"},{"key":"1484_CR25","volume-title":"Arthritis and Influenza Update","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention: Arthritis and Influenza Update. 2010, Atlanta, GA, USA: CDC, 14 September 2010.http:\/\/www.cdc.gov\/arthritis\/flu.htm, -2011,"},{"key":"1484_CR26","first-page":"1","volume":"59","author":"AE Fiore","year":"2010","unstructured":"Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ, Centers for Disease Control and Prevention (CDC): Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010, 59: 1-62.","journal-title":"MMWR Recomm Rep"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-13-158\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:28:24Z","timestamp":1630528104000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-13-158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-13-158","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,27]]},"assertion":[{"value":"15 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"158"}}